1stOncology™: Cancer Intelligence Service – Page 9988 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Bio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio

On February 3, 2021 Bio-Techne Corporation (NASDAQ: TECH) reported that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to include nine new cartridge formats (Press release, Bio-Techne, FEB 3, 2021, View Source [SID1234574534]). These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge. Simple Plex assay cartridges, run on the EllaTM platform, utilizing state-of-the-art microfluidics to deliver a fully automated immunoassay solution. Researchers can customize cartridge lots from a menu of over 200 validated assays. Until now, Simple Plex assay cartridges were only available in formats delivering one, four, or eight assays run simultaneously. The expanded portfolio of cartridge offerings provides users new options to better align their assay panels with the throughput requirements of their studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Dave Eansor, President of Bio-Techne’s Protein Sciences Segment commented, "This expanded selection of Simple Plex cartridges offers researchers the flexibility to automate their immunoassay workflow for projects of any scope or size using the Ella platform."

The Ella platform allows users to perform high-quality immunoassays with no manual intervention, enabling sub-picogram level sensitivity, 4+ logs of dynamic range and a high level of reproducibility. Ella’s innovative immunoassay workflow decreases the potential for user error and empowers staff to spend their time on higher value activities. Factory calibration of each Simple Plex assay cartridge eliminates the need to generate standard curves. Setting up an assay simply requires loading diluted samples into the cartridge. Once loaded, the Ella instrument performs every step of the immunoassay automatically, from wash steps to final quantification of results in just 90 minutes.

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

On February 3, 2021 Veracyte, Inc. (Nasdaq: VCYT) reported preliminary results for the fourth quarter and full year ended December 31, 2020 (Press release, Veracyte, FEB 3, 2021, View Source [SID1234574533]).

The company expects to report total revenue of between $34.0 million and $35.0 million and product and testing volume of between 13,000 and 13,200 tests for the fourth quarter ended December 31, 2020, an increase of 16% and 14% at the midpoint of the range, respectively, compared to the fourth quarter of 2019. The company expects to report total revenue of between $117.0 million and $118.0 million and product and testing volume of between 44,400 and 44,600 tests for the full year ended 2020, compared to $120.4 million and 40,292 tests for full-year 2019. In addition, the company expects to report cash and cash equivalents of between $345.0 million and $350.0 million as of December 31, 2020.

"We continued the strong rebound in our business during the fourth quarter, with revenue and genomic testing and product volume exceeding pre-pandemic levels," said Bonnie Anderson, Veracyte’s chairman and chief executive officer. "Moreover, I am incredibly proud of our team’s performance throughout 2020 as we advanced our vision of improving outcomes for patients all over the world at every step of their journey. With our comprehensive menu of advanced genomic tests that address unmet needs across the care continuum, our platform for serving global markets and our robust pipeline, we believe we are well-positioned for long-term, sustained growth."

The preliminary revenue and cash information presented in this press release is based on Veracyte’s current expectations, is unaudited and may be adjusted as a result of, among other things, the completion of Veracyte’s quarterly and annual financial closing procedures and audit by Veracyte’s independent registered public accounting firm. Actual results may differ materially from those disclosed in this press release. Veracyte will report its full financial results and other metrics during its fourth quarter and full-year 2020 financial results later this month.

GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER

On February 3, 2021 GlaxoSmithKline reported that Strong growth of new and specialty products; on track to deliver two exciting new companies (Press release, GlaxoSmithKline, FEB 3, 2021, View Source [SID1234574532])

Strong sales performance from key growth drivers in HIV, Respiratory, Oncology and Consumer Healthcare offset disruption from COVID-19 to adult vaccinations
Pharmaceuticals £17 billion -3% AER, -1% CER; new and specialty products £9.7 billion +11% AER, +12% CER
Vaccines £7 billion -2% AER, -1% CER. Shingrix £2 billion +10% AER, +11% CER
Consumer Healthcare £10 billion +12% AER, +14% CER (pro-forma -2% CER*)
New Biopharma product portfolio strengthened with 9 approvals in 2020 and Cabenuva in the US in January 2021
Effective cost control supports delivery of adjusted earnings per share in line with FY 2020 guidance
Total Group operating margin 22.8%. Total EPS 115.5p +23% AER, +26% CER
Adjusted Group operating margin 26.1%. Adjusted EPS 115.9p -6% AER, -4% CER
Q4 net cash flow from operations £4 billion. Free cash flow £3 billion
Significant progress on Biopharma pipeline with over 20 assets now in late-stage clinical trials
20+ new product launches planned by 2026, 10+ with potential peak annual revenues in excess of $1 billion
Pivotal study starts/data expected in 2021 for RSV vaccine in older adults, COVID-19 assets, long-acting anti IL-5 antagonist, daprodustat and dostarlimab
Oncology momentum building: 15 potential medicines in trials, including 9 immuno-oncology and 3 cell therapies
20+ deals executed, including acquisitions of new antibody, mRNA and genetics/genomics technologies
On track for separation into new standalone Biopharma and Consumer Healthcare companies in 2022
2020 targets met with £0.3 billion annual cost savings and £1.1 billion divestment proceeds achieved
Biopharma investor update in June to set out progress on innovation, commercial execution and growth outlook together with capital allocation priorities
Sustained progress and leadership in ESG
Sector leading in key indices, including DJSI and Sustainalytics, and #1 rank in 2021 Access to Medicines Index
New environmental targets set to achieve net zero impact on climate and net positive impact on nature by 2030
2021 Adjusted EPS expected to decline by a mid to high-single digit percentage in CER
Reflects further growth in new and specialty products and Consumer Healthcare, increased investment in our pipeline and deferral of strong growth in Vaccines performance due to impact of COVID-19 immunisation programmes
2022 outlook remains unchanged. Continue to expect meaningful improvement in revenues and margins
Dividend of 23p/share declared for Q4 2020; 80p/share for FY 2020. Expected dividend of 80p/share for FY 2021
Distribution policy for new GSK to be implemented in 2022 to support growth and investment. Aggregate distributions expected to be lower than at present
Emma Walmsley, Chief Executive Officer, GSK said:
"2020 was an extraordinary year for all of us, and one of significant ogress for GSK. We invested in our pipeline and new launches, readied the company for separation, and had to rapidly mobilise and respond to the pandemic. I am extremely proud of the agility and resilience our teams have shown. We delivered our guidance for the year, offsetting the significant impact of COVID-19 on adult vaccinations, with strong performances of new products and effective cost control.

"Importantly, progress against our strategic goals remains firmly on track. We are building a high value biopharma pipeline, have substantially integrated our Consumer JV and have delivered all our first year targets for our two year separation programme. This means we are in a strong position to launch new competitive, standalone Biopharma and Consumer healthcare companies in 2022. In doing so, we have high confidence that we can achieve meaningful global impact to health and significant value creation for shareholders."

Chi-Med to Announce 2020 Final Results

On February 3, 2021 Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) reported that it will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST) (Press release, Hutchison China MediTech, FEB 3, 2021, https://www.chi-med.com/chi-med-to-announce-2020-final-results/ [SID1234574531]).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.

The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas

On February 3, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas (Press release, Innate Pharma, FEB 3, 2021, View Source [SID1234574530]). The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.

The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:

Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator of Innate’s Phase 2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis fungoides and Sézary syndrome; and
Olivier Hermine, M.D., Professor of Hematology at the University of Paris Descartes and Director, Division of Adult Hematology at Hôpital Universitaire Necker Enfants Malades, Member of the Académie des Sciences, Member of the Lymphoma Study Association (LYSA), France
Presenters will provide an overview of the treatment landscape and prevalence of the lacutamab target, KIR3DL2, across subtypes of T-cell lymphoma. They will also highlight the potential impact of lacutamab in current and upcoming clinical programs in cutaneous and peripheral T-cell lymphomas.

Details for the Virtual Event

The live webcast of the event will be available at the following link:
View Source

A telephone number will also be made available. Participants may register in advance of the event at View Source Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.

A replay of the webcast will be archived on Innate’s website for 90 days following the event.

This information can also be found in the Investors section of the Innate website, www.innate-pharma.com.

About Lacutamab:
Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with peripheral t-cell lymphoma (PTCL). It has a restricted expression on normal tissues.